AARTI DRUGS LTD. - 524348 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of Loss of Share Certificate03-03-2023
03-03-2023
AARTI DRUGS LTD. - 524348 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of Loss of Share Certificate under Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201524-02-2023
AARTI DRUGS LTD. - 524348 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of Loss of Share Certificate under Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201514-02-2023
AARTI DRUGS LTD. - 524348 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Transcript of Q3 FY23 Earning Conference Call03-02-2023
AARTI DRUGS LTD. - 524348 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Recording of Conference Call30-01-2023
Q3FY23 Quarterly Result Announced for Aarti Drugs Ltd.
Aarti Drugs announced Q3FY23 results: Consolidated Q3FY23: Revenue stood at Rs 1,975.0 crore as against Rs 1,802.7 crore, a growth of 10% YoY. EBITDA stood at Rs 213.4 crore as against Rs 251.8 crore YoY. EBITDA margin (%) came in at 10.8%. PAT stood at Rs 110.2 crore as against Rs 149.7 crore YoY. PAT margin (%) stood at 5.6%. Consolidated 9MFY23: Revenue stood at Rs 665.0 crore as against Rs 641.5 crore, a growth of 4% YoY. EBITDA stood at Rs 71.7 crore as against Rs 96.7 crore YoY. EBITDA margin (%) came in at 10.8%. PAT stood at Rs 36.7 crore as against Rs 58.3 crore YoY. PAT margin (%) stood at 5.5%. Standalone Q3FY23: Standalone Q3FY23 revenue stood at Rs 626.5 crore as against Rs 594.8 crore, a growth of 5% YoY. The standalone business contributed ~92% to the consolidated revenue for the quarter. 61% of the revenues came from the domestic market and 39% from the export market for Q3FY23 for a standalone business. Domestic revenue grew approximately by 8% while exports grew by around 2% YoY for Q3FY23. Within the API business, the antibiotic therapeutic category contributed ~45%, anti-diabetic ~16%, anti-protozoal ~16%, anti-inflammatory ~12%, antifungal ~8% and the rest contributed ~3% to total API sales for Q3FY23. Segment: Q3FY23 revenue for formulation stood at Rs 49.9 crore as against Rs 54.9 crore. ~39% of the revenue came from exports during the quarter. Commenting on the results Mr. Adhish Patil, Chief Financial Officer – Aarti Drugs Limited said, “The company’s overall API revenue for the quarter grew by 9% YoY. However, due to a correction in raw material prices, the company made some price adjustments in order to defend its market share. Owing to API price correction, the company undertook inventory loss of approx. Rs 6 crores as a prudent practice. All of this weighed on the gross margins by almost ~100 bps during the quarter. The company has increased the inventory levels of imported KSMs and other raw materials due to a sudden spike of Covid-19 cases and holidays related to a new year in China. API sales volume in exports were affected to some extent due to shortage of US Dollar in many countries. The finance cost also increased due to higher working capital requirements and rising interest rates. The company has already received commitments from the customers for the brownfield expansion products as well as has received committed line of order for a campaign based product. As a result, the company is eyeing to double the revenue from Specialty Chemicals business within the next 12 months through the ongoing brownfield expansion. Formulation segment revenue stood at Rs 49.9 crore for the quarter. The formulation segment contributed 8% to the consolidated revenue for the quarter. The company’s core focus remains on growing the exports revenue. The capex for 9MFY23 stood at Rs 115 crore and is expected to be in the range of Rs 200-250 crore for the entire FY23. Tarapur greenfield facility is expected to be completed well within the timeline which will enable the company to foray into new API therapy of Dermatology. The construction activity for the Gujarat capex has also been ramped up. Tarapur specialty chemicals facility will be fully ramped up post the installation of equipments which are being imported. These equipments are expected to arrive by April 2023. The company’s various capex initiatives are expected to be completed and fully scaled up over the period of next 2 years in a phased manner and are expected to bolster the topline and profitability growth.” Result PDF30-01-2023
AARTI DRUGS LTD. - 524348 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release on Financial Results for the quarter and nine months ended December 31, 2022.27-01-2023